GLP-1 Side Effects: A Physician Protocol for Managing Them Safely

The Honest Side Effect Profile

Most patients tolerate GLP-1 therapy well. That is the truth, and it deserves to be said before the list. But honesty also requires the list, because a patient who is told to expect nothing and then feels something will lose trust in the clinician who promised a smooth ride.

The commonest side effect is nausea. It usually appears in the first week after a dose increase and fades within a few days as the body adjusts. Constipation is next, followed by occasional diarrhoea, early satiety to the point of discomfort, sulphur burps that some patients describe as the most socially inconvenient symptom, and a flat fatigue in week one to two that lifts as energy returns. Headache, mild dizziness on standing, and a transient drop in mood during the first fortnight are reported less often but are real.

Serious events are rare. Acute pancreatitis is the headline risk and presents with severe upper abdominal pain radiating to the back. Severe gastroparesis with persistent vomiting and dehydration is uncommon but documented. Gallbladder events are slightly more frequent during rapid weight loss with any therapy, GLP-1 included.

In STEP 1, fewer than five percent of participants discontinued for gastrointestinal reasons. In clinical practice with structured titration, the discontinuation rate is even lower.

Why Side Effects Happen

GLP-1 receptor agonists do three things at once. They slow gastric emptying, they enhance satiety signalling in the hypothalamus, and they activate vagal afferent fibres that report to the brainstem. These same mechanisms are responsible for the therapeutic effect. You cannot have the appetite suppression without the slowed stomach. The two are not separable.

Understanding this changes how a patient interprets the symptoms. Nausea is not the medication failing. It is the medication working at a dose that is, for the moment, slightly higher than the patient's biology is ready for. The fix is rarely to stop. The fix is usually to slow down.

The DermaVue Titration Protocol

For semaglutide, the standard escalation is 0.25 mg weekly for four weeks, then 0.5 mg weekly for four weeks, then 1.0 mg, then 1.7 mg, then 2.4 mg, with each step held until the patient is comfortable. For tirzepatide, the analogous ladder runs 2.5 mg weekly upward in 2.5 mg increments at four-week intervals.

The DermaVue rule is simple. We never increase a dose into active side effects. If a patient at the end of week four is still nauseous on 0.25 mg, the next four weeks remain at 0.25 mg. There is no medal for fast titration. The destination dose matters far less than arriving at it without a failed protocol.

We also use a skip-dose rule. If a single weekly dose produces unmanageable symptoms, the next dose may be delayed by 24 to 48 hours under physician guidance, and the dose after that is held flat until comfort returns. This is structured, not improvised.

Nausea Management Ladder

Nausea is the symptom patients most fear and the one most amenable to intervention. We escalate in five clear steps and we move up only when the previous step has failed.

1. 1

   Eating pattern and hydration

   Three small meals replace one large one. Dinner is the lowest-fat meal of the day, eaten three hours before bed. Fluids are sipped, not gulped, between meals rather than with them. Trigger foods, usually fried items and heavy dairy, are removed for two weeks.

2. 2

   Ginger, peppermint, oral rehydration therapy

   Ginger in South Indian forms has genuine anti-emetic activity. Peppermint tea after meals helps some patients. If appetite has dropped enough that fluid intake is suffering, an oral rehydration solution sipped through the day prevents secondary fatigue from dehydration.

3. 3

   Over-the-counter antacids

   A simple antacid before the evening meal manages the reflux component that some patients develop from delayed gastric emptying. Calcium-free options are chosen where possible to avoid constipation interaction.

4. 4

   Physician-prescribed anti-emetics

   When the first three steps are insufficient, a short course of ondansetron 4 mg or domperidone may be prescribed under medical supervision, timed to the day after the weekly injection when symptoms typically peak. We do not initiate this without a clinical contact.

5. 5

   Pause and reassess

   If steps one through four fail, the medication is paused, the patient is reviewed in person, and the protocol is reconsidered. Sometimes the answer is a slower titration, sometimes a switch between molecules, and sometimes a different strategy entirely.

The Gastroparesis Question

Severe, persistent gastroparesis is the side effect that has attracted the most media attention. It is rare. It is also serious when it happens. We screen for prior gastroparesis history at the first consultation. We watch for warning signs throughout therapy: vomiting that recurs more than twice in a week beyond the titration window, inability to keep fluids down, unintentional rapid weight loss outside the expected range, and a sense of fullness that lasts hours after eating.

Constipation Protocol

Slowed gastric emptying often produces slowed colonic transit. The protocol is straightforward and runs in parallel with nausea management.

Hydration first. Two to two and a half litres of water daily, more in summer. Psyllium husk, the isabgol available in any Indian pharmacy, one to two teaspoons in water at night. Magnesium glycinate or citrate at bedtime, dose adjusted to response. A fibre ladder added gradually so that the gut is not shocked: vegetables at every meal, fruit twice daily, whole grains where tolerated. If these fail, a short course of an osmotic laxative such as polyethylene glycol is appropriate under physician guidance. Stimulant laxatives are reserved for short, supervised use only.

When to Pause and Call Your Physician

The Lab Panel You Should Have

Before starting GLP-1 therapy at DermaVue, every patient completes a structured panel. We repeat the metabolic and lipid panel at three months, the lipase if any abdominal symptom develops, and the renal function if the patient has any prior nephrology history. This is the minimum standard of care for a medication of this potency and it is non-negotiable. A clinic that prescribes GLP-1 without baseline labs is not practising medicine. It is filling a prescription.

The Psychological Side

The physical side effects are easier to map than the psychological ones, but the psychological ones are often more important.

Many patients experience an unexpected grief when food stops being interesting. The relationship with eating is not just calories. It is celebration, comfort, family, identity. When appetite falls suddenly, that whole architecture wobbles. We talk about this at the first visit and we revisit it at week six. It passes, but it should be named.

Muscle loss anxiety is the second psychological pressure point. Patients have read that GLP-1 produces lean mass loss alongside fat loss. This is true and it is the reason our protocol pairs the medication with a structured resistance training prescription and a daily protein floor of 1.6 grams per kilogram of ideal body weight. Body composition is what we track, not just the scale.

The third pressure point is rebound fear. The honest answer is that some patients regain weight when they stop, and some maintain. We design every protocol with the exit conversation built in from week one. A patient who knows the plan does not panic about the future.